Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Active not recruiting 5Recruiting 4Withdrawn 2Not yet recruiting 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Prostatic Neoplasms 25Breast Neoplasms 21Glioblastoma 19Carcinoma, Non-Small-Cell Lung 17Sarcoma 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Rectal Neoplasms 8Neoplasms 8Hodgkin Disease 8Head and Neck Neoplasms 8Brain Neoplasms 8Oropharyngeal Neoplasms 7Glioma 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 6Astrocytoma 6Triple Negative Breast Neoplasms 5Lymphoma 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Neoplasm Metastasis 4Melanoma 4Medulloblastoma 4Histiocytoma, Malignant Fibrous 4Small Cell Lung Carcinoma 3Rhabdomyosarcoma 3Recurrence 3

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 14Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5capivasertib 4Epirubicin 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Fulvestrant 3Blood Specimen Collection 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × Radiotherapy × Clear all
NCT02954874 2026-06-03

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,155 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04052555 2026-05-13

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

University of Nebraska

Phase 2 Active not recruiting
92 enrolled 17 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04837209 2025-10-01

NADiR

Massachusetts General Hospital

Phase 2 Active not recruiting
32 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

Massachusetts General Hospital

Phase 1 Active not recruiting
21 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡